Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate dose-dependent effects of low dose colchicine on
inflammatory responses, endothelial function in type 2 diabetic patients with coronary artery
disease and leukocyte activation. This study also tested the relationship between doses and
safety issue such as incidence of diarrhea. Eligible patients will be randomly allocated to
three treatment group: colchicine at 0.5mg per day, 0.25mg per day or placebo for 12 weeks in
a double blind , parallel group design. High sensitive-CRP at 4 weeks as primary end point
and flow mediated vasodilatation at 12 weeks as the secondary end point will be measured.